Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Major histocompatibility complex binding peptides: a target for therapeutic development.

A Sette1, P Wentworth, H M Grey

  • 1Cytel, San Diego, California.

Current Opinion in Biotechnology
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune signatures underlying post-acute COVID-19 lung sequelae.

Science immunology·2021
Same author

Pathways to post-traumatic growth in cancer patients: moderated mediation and single mediation analyses with resilience, personality, and coping strategies.

Journal of affective disorders·2020
Same author

An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.

Vaccine·2020
Same author

Cripto-1 vaccination elicits protective immunity against metastatic melanoma.

Oncoimmunology·2016
Same author

Sequence conservation predicts T cell reactivity against ragweed allergens.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016
Same author

Lack of allergy to timothy grass pollen is not a passive phenomenon but associated with the allergen-specific modulation of immune reactivity.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015

High-affinity peptides targeting major histocompatibility complex molecules show promise for autoimmune diseases like rheumatoid arthritis. Further research is needed to overcome challenges before therapeutic application.

Area of Science:

  • Immunology
  • Molecular Biology
  • Therapeutics

Background:

  • Major histocompatibility complex (MHC) molecules present antigens to T cells, playing a critical role in immune responses.
  • Class II-associated autoimmune diseases, including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, involve aberrant immune responses.
  • Targeting MHC molecules with high-affinity peptides is a potential therapeutic strategy.

Purpose of the Study:

  • To explore the therapeutic potential of high-affinity peptides that bind to major histocompatibility complex (MHC) molecules.
  • To evaluate the feasibility of using these peptides for treating class II-associated autoimmune diseases.
  • To identify challenges hindering the development of effective peptide-based therapies.

Main Methods:

Related Experiment Videos

  • In vitro studies using purified receptor systems.
  • In vivo experiments with cellular systems.
  • High-affinity peptide binding assays to MHC molecules.

    • Main Results:

    • Proof-of-concept validation for peptide binding to MHC molecules.
    • Demonstration of potential therapeutic utility in experimental models.
    • Identification of significant challenges in translating this concept to clinical application.

    Conclusions:

    • High-affinity peptides targeting MHC molecules offer a promising avenue for autoimmune disease treatment.
    • Experimental validation supports the therapeutic concept.
    • Further research and problem-solving are essential for developing efficacious peptide-based therapeutics.